why choose us

Clinical Trials Search

Showing 19,480 of 132,963 result(s)
Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

Status: Active, not recruiting

Condition: Melanoma

Interventions: Not Provided

Date: 2022-09-16

Linezolid for Syphilis Pilot Study

Status: Completed

Condition: Syphilis

Interventions: Oral Linezolid 600mg, taken twice a day for 10 days

Date: 2022-09-16

Reduced Opioid Prescription After Laparoscopic Hysterectomy

Status: Completed

Condition: Pain, Postoperative

Interventions: No opioid prescription after laparoscopic hysterectomy

Date: 2022-09-16

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

Status: Completed

Condition: Brain Metastases

Interventions:

SRS and oral tucatinib for 2 wk, followed by oral tucatinib, oral capecitabine, and intravenous (IV) trastuzumab maintenance during 21-d cycles unt

Date: 2022-09-16

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

Status: Completed

Condition: Cystic Fibrosis

Interventions: Intravenous (IV) ?-lactam will be selected by the treating physician following standard of care.
Treatment will last for 14 days (± 2 days).

Date: 2022-09-16

Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge

Status: NOT_YET_RECRUITING

Condition: Diabetes

Interventions: Manufactured by Abbott Diabetes Care Inc.
Administered by trained investigator prior to hospital discharge, left in place for 2 weeks duration, t

Date: 2022-09-16

The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure

Status: Completed

Condition: Obesity

Interventions: +200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat

Date: 2022-09-16

Empagliflozin in ESKD - A Feasibility Study

Status: NOT_YET_RECRUITING

Condition: Kidney Failure, Chronic

Interventions: Participants in Group I will be asked to take empagliflozin 25 mg after each hemodialysis session under direct observation by a trained health care wo

Date: 2022-09-16

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

Status: Completed

Condition: Brain Metastases

Interventions: Patients will receive 5-mCi dose (+;- 20%) of 18F-Fluciclovine intravenously as a bolus injection.
They will be required to fast for at leas

Date: 2022-09-16

Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain

Status: NOT_YET_RECRUITING

Condition: Pain Management

Interventions: The plan will be to stratify patients in two groups: intervention group receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg [3 mg;mL], Keto

Date: 2022-09-16